LUPIN

May 28 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN’S ANKLESHWAR FACILITY RECEIVES EIR FROM U.S. FDA

Further company coverage: LUPN.NS

(([email protected];;))

May 22 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES CHINA APPROVAL FOR OSELTAMIVIR PHOSPHATE ORAL SUSPENSION

Source text: [ID:]

Further company coverage: LUPN.NS

(([email protected];))

May 13 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - LUPIN RECEIVES U.S. FDA APPROVAL FOR FAMOTIDINE INJECTION, USP

Source text: ID:nnAZN4SW0AC

Further company coverage: LUPN.NS

(([email protected];))

** India's Lupin LUPN.NS posted a profit of 14.6 billion rupees ($154.5 million) in Q4, up 89% Y/Y

** Shares of LUPN down ~4% to 2,364.3 rupees, after gaining about 5% in the previous two sessions ahead of earnings

STRONG U.S. MOMENTUM, INDIA RECOVERY

** Macquarie ("outperform", TP:2,460 rupees) sees strong visibility on co's upcoming U.S. launches and the resilience of its well-established domestic business

** Morgan Stanley ("equal-weight", TP:2,386 rupees) says Q4 results were driven by strong growth in its U.S. business due to new product launches and steady base business expansion; says India business resilient, supported by healthy growth in key therapies

** Nomura ("buy", PT:2,580 rupees) says margin expansion was supported favorable currency movements and a recovery in India growth, although overhead costs rose partly due to expenses related to the VISUfarma acquisition

($1 = 94.4725 Indian rupees)

(Reporting by Devika Nair in Bengaluru)

(([email protected];))

May 7 (Reuters) - Lupin Ltd LUPN.NS:

• MARCH-QUARTER CONSOL NET PROFIT 14.6 BILLION RUPEES

• MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 74.75 BILLION RUPEES

• DIVIDEND 18 RUPEES PER SHARE

Further company coverage: LUPN.NS

(([email protected];;))

May 5 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES U.S. FDA APPROVAL FOR GLYCEROL PHENYLBUTYRATE ORAL LIQUID

Source text: ID:nBSE3DnMTs

Further company coverage: LUPN.NS

(([email protected];))

April 22 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN LAUNCHES DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS IN THE UNITED STATES

Source text: ID:nPn8H4D2Na

Further company coverage: LUPN.NS

(([email protected];;))

April 17 (Reuters) - Lupin Ltd LUPN.NS:

• INCORPORATES WHOLLY OWNED SUBSIDIARY LUPIN (THAILAND) LIMITED IN THAILAND ON APRIL 17, 2026

Source text: ID:nBSE2RP5Bv

Further company coverage: LUPN.NS

(([email protected];;))

April 10 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - LAUNCHES DAPAGLIFLOZIN TABLETS IN THE UNITED STATES

Source text: ID:nnAZN4SQ8JK

Further company coverage: LUPN.NS

(([email protected];;))

April 8 (Reuters) - Lupin Ltd LUPN.NS:

• ANNOUNCES APPROVAL OF DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS IN UNITED STATES

Further company coverage: LUPN.NS

(([email protected];;))

Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR SUGAMMADEX INJECTION

Source text: [ID:]

Further company coverage: LUPN.NS

** Shares of Indian drugmaker Lupin LUPN.NS rise nearly 1% to 2366 rupees

** Co on Wednesday received tentative approval From U.S. FDA for Pitolisant tablets, to treat excessive daytime sleepiness in kids aged six and older people with narcolepsy

** Approval for Lupin's Pitolisant Tablets 4.45mg and 17.8 mg as bioequivalent to Wakix, co says

** More than 208,915 shares change hand by 11.11 am IST vs 30-day avg of 928,638 shares

** LUPN rated "buy" on avg by 35 analysts covering it; median PT at 2436 rupees

** YTD, LUPN up 11%

(Reporting by Komal Salecha in Bengaluru)

(([email protected]))

Lupin Ltd LUPN.NS:

• LUPIN RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR PITOLISANT TABLETS

• LUPIN - RECEIVES TENTATIVE FDA APPROVAL FOR PITOLISANT TABLETS 4.45MG AND 17.8MG

Source text: ID:nPn8nqFXza

Further company coverage: LUPN.NS

March 19 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - LUPIN MANUFACTURING SOLUTIONS ANNOUNCES EXPANSION OF MANUFACTURING FACILITY AT DABHASA, INDIA

• LUPIN - MANUFACTURING SOLUTIONS ANNOUNCES EXPANSION OF DABHASA FACILITY

Source text: ID:nBSE90Bc0x

Further company coverage: LUPN.NS

(([email protected];))

March 17 (Reuters) - Lupin Ltd LUPN.NS:

• CO AND LUPIN SIGN LICENSING AGREEMENT FOR CO-MARKETING INNOVATIVE SEMAGLUTIDE INJECTION IN INDIA

Further company coverage: LUPN.NS

(([email protected];;))

March 2 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - TAX DEPARTMENT CONCLUDES INSPECTION AT LUPIN'S REGISTERED OFFICE

• LUPIN - NO IMPACT ON LUPIN'S FINANCIALS FROM GST PROCEEDINGS

• LUPIN - NO ADVERSE FINDINGS ISSUED BY TAX DEPARTMENT TO CO

Source text: ID:nNSE6drzdm

Further company coverage: LUPN.NS

(([email protected];))

Feb 27 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - VISUFARMA B.V. DEAL ANTICIPATED TO COMPLETE IN APRIL 2026

Source text: ID:nNSE3ylQqz

Further company coverage: LUPN.NS

(([email protected];))

Feb 25 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - TAX DEPARTMENT INITIATED INSPECTION AND SEARCH AT CO

• LUPIN - INSPECTION, SEARCH DOESN’T HAVE ANY IMPACT ON CO'S FINANCIALS, OPERATIONS

Further company coverage: LUPN.NS

(([email protected];))

Feb 24 (Reuters) - Lupin Ltd LUPN.NS:

• RECEIVES FDA APPROVAL FOR BRIVARACETAM ORAL SOLUTION

Source text: ID:nBSE2nrh2j

Further company coverage: LUPN.NS

(([email protected];;))

Feb 23 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES EUROPEAN COMMISSION APPROVAL FOR BIOSIMILAR RANIBIZUMAB

Further company coverage: LUPN.NS

(([email protected];))

** Shares of India's Lupin LUPN.NS rise 1.35% to 2249.80 rupees

** Drugmaker signs license and supply agreement with Spektus Pharma to commercialize antidepressant Deslaflex in Canada

** Co says deal expands Lupin's central nervous system (CNS) portfolio in the Canadian market

** Trading vols at 424,238 shares vs 30-day-avg of 873,939 shares

** Stock rated "buy" on avg by 35 analysts, median PT at 2421.50 rupees

** LUPN dropped 10.45% in 2025, stock gained 5.3% so far in 2026

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

Feb 16 (Reuters) - Lupin Ltd LUPN.NS:

• SIGNS LICENSE AND SUPPLY AGREEMENT WITH SPEKTUS TO COMMERCIALIZE NOVEL ANTIDEPRESSANT DESLAFLEX IN CANADA

Further company coverage: LUPN.NS

(([email protected];;))

By Rishika Sadam

Feb 13 (Reuters) - Biocon BION.NS is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it remains cautious about an early rollout in the home market, a top company executive told Reuters.

The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's NOVOb.CO Wegovy, whose patent for semaglutide in a few markets expires in 2026.

Indian drugmakers, including Dr Reddy's REDY.NS, Lupin LUPN.NS, Sun Pharmaceutical SUN.NS and at least half a dozen others are racing to bring cheaper copies to markets once the active compound goes off patent.

Bengaluru-based Biocon is targeting a U.S. launch of generic liraglutide in the first quarter of the next financial year, CEO Siddharth Mittal said in an interview on Friday. Liraglutide is also used for obesity treatment.

It aims to launch generic Wegovy in Canada next year, subject to regulatory approval, Mittal said. It is also planning launches over the next few years in India, Brazil, Mexico, Turkey, and parts of the Middle East and Latin America.

The company, however, is cautious about an early start in India due to fierce price competition and local clinical trial requirements, Mittal said.

"There's going to be fierce competition in India," Mittal said, citing low price expectations. He said Biocon is exploring approval in a specific overseas market first, which could help it seek a clinical trial waiver in India under local rules.

In India, Biocon would need to run a late-stage clinical trial before launch. The company is weighing whether that cost would be justified, Mittal said, or whether it should seek a waiver.

The obesity medicines market, according to several forecasts, is expected to reach at least $150 billion globally by the early 2030s, and analysts expect generic versions to be priced at least 60% below the originator products.

Biocon expects high double-digit percentage revenue growth, Mittal said. The company's annual revenue grew 5.4% in fiscal 2025 from a year ago, but it has been growing in early double-digits on a quarter-on-quarter basis.

India is not Biocon's main market. The company derives significant share of revenue from the United States and parts of Europe.

(Reporting by Rishika Sadam; Editing by Tasim Zahid)

(([email protected];))

Adds stock prices in paragraph 4

Feb 12 (Reuters) - India's Zydus Lifesciences ZYDU.NS and its U.S. unit will pay $120 million to Astellas Pharma 4503.T as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron, the Indian firm said on Thursday.

Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the U.S. from the date of the agreement until September 2027, the company said.

The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions of the agreement are confidential.

Shares of Zydus climbed as much as 1.3% shortly after the announcement.

The announcement comes days after local peer Lupin LUPN.NS decided to settle its dispute with Astellas over the same drug for $90 million.

At that time, analysts at brokerage Citi said the development could delay the entry of other generic rivals in the U.S. market, potentially providing Zydus and Lupin with a period of limited competition.

(Reporting by Hritam Mukherjee in Bengaluru; Editing by Sherry Jacob-Phillips)

((mailto: [email protected]; @MukherjeeHritam;))

Feb 10 (Reuters) - Lupin Ltd LUPN.NS:

• ENTERS SETTLEMENT AND LICENSE AGREEMENT WITH ASTELLAS

• TO PAY ASTELLAS $90 MILLION

• PREPAID PER UNIT LICENSE FEE FOR EACH UNIT SOLD FROM SETTLEMENT THROUGH SEPTEMBER 2027

Source text: ID:nNSE1RKHf2

Further company coverage: LUPN.NS

(([email protected];;))

Feb 4 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - LAUNCHES TOPIRAMATE EXTENDED-RELEASE CAPSULES IN U.S.

Source text: ID:nBSE79Kl58

Further company coverage: LUPN.NS

(([email protected];))

Feb 2 (Reuters) - Lupin Ltd LUPN.NS:

• LAUNCHES DASATINIB TABLETS IN THE UNITED STATES

Source text: ID:nnAZN4S7KLI

Further company coverage: LUPN.NS

(([email protected];;))

Jan 21 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - LUPIN AND GALENICUM SIGN LICENSE AND SUPPLY AGREEMENT FOR SEMAGLUTIDE IN 23 COUNTRIES

• LUPIN - GALENICUM TO OVERSEE DEVELOPMENT, LUPIN TO HANDLE COMMERCIALIZATION

• LUPIN - AGREEMENT COVERS 23 COUNTRIES INCLUDING CANADA AND EUROPE

Source text: ID:nBSE3r0Rd

Further company coverage: LUPN.NS

(([email protected];))

Dec 29 (Reuters) - Lupin Ltd LUPN.NS:

• SIGNS EXCLUSIVE LICENSING AGREEMENT WITH GAN & LEE PHARMACEUTICALS FOR NOVEL GLP-1 RECEPTOR AGONIST

Source text: ID:nNSE2BTscP

Further company coverage: LUPN.NS

(([email protected];))

Dec 19 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:

• BIOMARIN TO ACQUIRE AMICUS THERAPEUTICS FOR $4.8 BILLION, EXPANDING POSITION AS A LEADER IN RARE DISEASES, ACCELERATING REVENUE GROWTH AND STRENGTHENING FINANCIAL OUTLOOK

• AMICUS THERAPEUTICS INC - BIOMARIN TO BUY AMICUS FOR $14.50 PER SHARE IN CASH

• AMICUS THERAPEUTICS INC - BIOMARIN TO FINANCE DEAL WITH CASH AND $3.7 BILLION DEBT

• AMICUS THERAPEUTICS INC: DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP DILUTED EARNINGS PER SHARE IN FIRST 12 MONTHS POST-CLOSE

• AMICUS THERAPEUTICS INC: PENDING U.S. GALAFOLD IP LITIGATION RESOLVED

• AMICUS THERAPEUTICS : DEAL SUBSTANTIALLY ACCRETIVE TO NON-GAAP DILUTED EPS BEGINNING IN 2027 TO BIOMARIN

• AMICUS THERAPEUTICS: ENTERED LICENSE AGREEMENTS WITH AUROBINDO & LUPIN FOR GALAFOLD 123 MG CAPSULES

• AMICUS THERAPEUTICS: TO GRANT AUROBINDO AND LUPIN LICENSES TO MARKET GENERIC VERSIONS OF GALAFOLD IN US FROM JAN 30, 2037

Source text: ID:nPn6mkX9xa

Further company coverage: BMRN.O

(([email protected];))